{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T11:41:11Z","timestamp":1774525271031,"version":"3.50.1"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:00:00Z","timestamp":1670457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Few data exist on the immunogenicity and safety of an inactivated enterovirus 71 vaccine (EV71 vaccine) coadministered with trivalent split-virion inactivated influenza vaccine (IIV3) in infants.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This trial was a phase 4, randomized, controlled trial. Infants aged 6-11 months were eligible, with no history of hand, foot and mouth disease (HFMD) and no history of EV71 vaccine or any influenza vaccine. Eligible infants were randomly assigned to EV71+IIV3 group, EV71 group or IIV3 group. Blood samples were collected on day 0 and 56.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Between September 2019 and June 2020, 1151 infants met eligibility criteria and 1134 infants were enrolled. 1045 infants were included in the per-protocol population, including 347 in the EV71+IIV3 group, 343 in the EV71 group, and 355 in the IIV3 group. The seroconversion rate (98.56% vs 98.54%; seroconversion rates difference of 0.02% [95% CI: 0.70-0.98]) and GMT (419.05 vs 503.72; GMT ratio of 0.83 [95% CI 0.70 - 0.98]) of EV71 neutralizing antibodies in the EV71+IIV3 group was not inferior to those in the EV71 group. The non-inferiority results for influenza virus antibodies (A\/H1N1, A\/H3N2 and B) showed that the seroconversion rates and GMTs of the EV71+IIV3 group were non-inferiority to those of the IIV3 group. Systemic and local adverse event rates were similar between groups. None of serious adverse events (SAEs) were related to vaccination.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Coadministration of the EV71 vaccine with IIV3 was safe and did not interfere with immunogenicity. These findings support a viable immunization strategy for infants with the EV71 vaccine coadministered with IIV3 in China. <\/jats:p><jats:p>This trial is registered with ClinicalTrials.gov, number NCT04091880.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.1080408","type":"journal-article","created":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T05:14:28Z","timestamp":1670476468000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Immunogenicity and safety of an inactivated enterovirus 71 vaccine coadministered with trivalent split-virion inactivated influenza vaccine: A phase 4, multicenter, randomized, controlled trial in China"],"prefix":"10.3389","volume":"13","author":[{"given":"Yaping","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanhui","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanqing","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linyun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lubin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuyue","family":"Mu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinghu","family":"Guan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoming","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1586\/14737159.7.4.419","article-title":"Basic rationale, current methods and future directions for molecular typing of human enterovirus","volume":"7","author":"Nasri","year":"2007","journal-title":"Expert Rev Mol diagnostics"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-018-3206-x","article-title":"Hand, foot and mouth disease: Current knowledge on clinical manifestations, epidemiology, aetiology and prevention","volume":"37","author":"Esposito","year":"2018","journal-title":"Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(10)70194-8","article-title":"Virology, epidemiology, pathogenesis, and control of enterovirus 71","volume":"10","author":"Solomon","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.716039","article-title":"Risk factors for severe hand-Foot-Mouth disease in China: A systematic review and meta-analysis","volume":"9","author":"Li","year":"2021","journal-title":"Front Pediatr"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(13)70342-6","article-title":"Hand, foot, and mouth disease in China, 2008-12: An epidemiological study","volume":"14","author":"Xing","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)33293-2","article-title":"Estimates of global seasonal influenza-associated respiratory mortality: A modelling study","volume":"391","author":"Iuliano","year":"2018","journal-title":"Lancet (London England)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/s2214-109x(19)30545-5","article-title":"Global burden of respiratory infections associated with seasonal influenza in children under 5 years in 2018: A systematic review and modelling study","volume":"8","author":"Wang","year":"2020","journal-title":"Lancet Global Health"},{"key":"B8","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/irv.12205","article-title":"The substantial hospitalization burden of influenza in central China: Surveillance for severe, acute respiratory infection, and influenza viruses, 2010-2012","volume":"8","author":"Yu","year":"2014","journal-title":"Influenza other Respir viruses"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2021.12.023","article-title":"Impact of non-pharmaceutical interventions during covid-19 pandemic on pertussis, scarlet fever and hand-Foot-Mouth disease in China","volume":"84","author":"Geng","year":"2022","journal-title":"J infection"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.1038\/s41467-021-23440-1","article-title":"Impact of covid-19 outbreaks and interventions on influenza in China and the united states","volume":"12","author":"Feng","year":"2021","journal-title":"Nat Commun"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.46234\/ccdcw2021.224","article-title":"Epidemiological and virological surveillance of seasonal influenza viruses - China, 2020-2021","volume":"3","author":"Huang","year":"2021","journal-title":"China CDC weekly"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.02.049","article-title":"Influenza vaccine effectiveness against influenza-associated hospitalization in children: A systematic review and meta-analysis","volume":"38","author":"Kalligeros","year":"2020","journal-title":"Vaccine"},{"key":"B13","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/s2352-4642(19)30185-3","article-title":"Effectiveness of ev-A71 vaccination in prevention of paediatric hand, foot, and mouth disease associated with ev-A71 virus infection requiring hospitalisation in henan, China, 2017-18: A test-negative case-control study","volume":"3","author":"Li","year":"2019","journal-title":"Lancet Child Adolesc Health"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2020.1804776","article-title":"Vaccines and routine immunization strategies during the covid-19 pandemic","volume":"17","author":"Dinleyici","year":"2021","journal-title":"Hum Vaccines immunotherapeutics"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(12)61764-4","article-title":"Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: A randomised, double-blind, placebo-controlled phase 2 clinical trial","volume":"381","author":"Zhu","year":"2013","journal-title":"Lancet (London England)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1304923","article-title":"Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China","volume":"370","author":"Zhu","year":"2014","journal-title":"New Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1093\/infdis\/jiw502","article-title":"2-year efficacy, immunogenicity, and safety of vigoo enterovirus 71 vaccine in healthy Chinese children: A randomized open-label study","volume":"215","author":"Wei","year":"2017","journal-title":"J Infect Dis"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1188","article-title":"Early evidence of inactivated enterovirus 71 vaccine impact against hand, foot, and mouth disease in a major center of ongoing transmission in China, 2011-2018: A longitudinal surveillance study","volume":"71","author":"Head","year":"2020","journal-title":"Clin Infect Dis an Off Publ Infect Dis Soc America"},{"key":"B19","doi-asserted-by":"publisher","first-page":"895","DOI":"10.3390\/vaccines10060895","article-title":"Immunogenicity and safety of an inactivated enterovirus 71 vaccine administered simultaneously with hepatitis b virus vaccine, group a meningococcal polysaccharide vaccine, measles-rubella combined vaccine and Japanese encephalitis vaccine: A multi-center, randomized, controlled clinical trial in China","volume":"10","author":"Liu","year":"2022","journal-title":"Vaccines"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2021.2010428","article-title":"Immunogenicity and safety of an inactivated enterovirus 71 vaccine Co-administered with measles-Mumps-Rubella vaccine and live-attenuated Japanese encephalitis vaccine: A phase 4, single-center, randomized controlled trial","volume":"17","author":"Liu","year":"2021","journal-title":"Hum Vaccines immunotherapeutics"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz129","article-title":"Immunogenicity and safety of an inactivated enterovirus 71 vaccine administered simultaneously with hepatitis b vaccine and group a meningococcal polysaccharide vaccine: A phase 4, open-label, single-center, randomized, noninferiority trial","volume":"220","author":"Zhang","year":"2019","journal-title":"J Infect Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2022.06.027","article-title":"Immunogenicity and safety of the inactivated enterovirus 71 vaccine administered concomitantly with the measles-rubella vaccine in infants aged 8 months in China: A noninferiority randomized controlled trial","volume":"40","author":"Zhao","year":"2022","journal-title":"Vaccine"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1080408\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T05:14:30Z","timestamp":1670476470000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1080408\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,8]]},"references-count":22,"alternative-id":["10.3389\/fimmu.2022.1080408"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1080408","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,8]]},"article-number":"1080408"}}